Medication info
Youzenta Duo Tablet 2.5/850 mg

Youzenta Duo Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Youyoung Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaged x 6)
Approval status
Active

MFDS item code 201900303 · Approved 2019.01.22

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Patients requiring cautious administration). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Patients requiring cautious administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Youyoung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
  • inadequate blood sugar control
View approved original text

This drug is used in conjunction with diet and exercise therapy to effectively help adults with type 2 diabetes control their blood sugar levels. It is administered in cases where patients have not previously used diabetes medications or have difficulty managing blood sugar alone. Additionally, it can be added when adequate effects are not achieved with monotherapy using metformin. Linagliptin and metformin combination therapy can either replace or be added when blood sugar control is difficult with metformin and sulfonylureas. It is also used when blood sugar control is inadequate in conjunction with insulin and metformin, and it is used when added to empagliflozin and metformin combination therapy. It is employed in various therapeutic situations to improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Patients requiring cautious administration). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for use, 3. Patients requiring cautious administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for use, 2. Do not administer to the following patients).

Precautions

This drug may cause serious side effects such as lactic acidosis, so it should not be administered to patients with poor kidney function, heart disease, or liver dysfunction. Patients who are allergic to the main ingredients of this drug or patients with type 1 diabetes, pregnant women, and nursing mothers should also refrain from use. Due to the risk of hypoglycemia, blood sugar should be closely monitored when used in conjunction with insulin or sulfonylurea medications, and dosage adjustments may be necessary if needed. Patients with decreased kidney function should undergo regular kidney function tests before and during treatment with this drug, and it should be avoided in cases of significant kidney function impairment. Patients with heart failure should also be treated with caution, and if symptoms of acute pancreatitis or blistering dermatosis occur, the drug should be stopped immediately and a physician should be consulted. This drug may lower vitamin B12 levels, so patients taking it long-term should regularly check their vitamin B12 levels. If iodinated contrast agents are required for radiological examinations, this drug should be stopped for a certain period before and after the examination, and it should be re-administered only after confirming safety through kidney function testing. Patients scheduled for surgery should stop taking this drug 48 hours prior to the surgery and resume after confirming that kidney function has normalized post-surgery. Women who are pregnant or may become pregnant should not take this drug and should consider using insulin for blood sugar control. Elderly patients often have reduced kidney function, so it’s safe to frequently check kidney function and start treatment at the lowest dose when taking this drug. This drug is not recommended for children or those under 10 years of age. In cases of overdose, lactic acidosis may occur, so immediate medical attention should be sought, and hemodialysis may be necessary. This drug should be kept out of reach of children and stored away from moisture. It is advisable to avoid alcohol consumption while taking this drug, and there may be potential interactions with other medications, so consultation with a physician or pharmacist is recommended. The impact on driving or operating machinery is not clear, so caution is advised.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • reduced and deficiency of vitamin B12
  • taste disorder
  • cough
  • decreased appetite
Show 120 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • arthralgia with severity and disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • respiratory distress
  • nosebleed
  • oropharyngeal pain
  • dysphonia
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • headache
  • drowsiness
  • chest discomfort
  • asthenia
  • pain
  • osteoarthritis
  • limb pain
  • pruritus
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • dizziness
  • diabetic neuropathy
  • subdural effusion
  • palpitations
  • confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 to 30 degrees Celsius. This will help preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaged x 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.